OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

Other equities analysts have also issued reports about the stock. Stephens reissued an “equal weight” rating and set a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Needham & Company LLC lifted their target price on OncoCyte from $3.60 to $4.25 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Finally, Benchmark reissued a “speculative buy” rating and set a $5.00 price target on shares of OncoCyte in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.06.

OncoCyte Trading Up 1.8 %

NASDAQ:OCX opened at $2.53 on Tuesday. The stock has a fifty day simple moving average of $2.89 and a 200-day simple moving average of $3.03. OncoCyte has a twelve month low of $2.08 and a twelve month high of $6.20.

Insider Transactions at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of OncoCyte stock in a transaction on Thursday, April 11th. The stock was bought at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the transaction, the insider now owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of OncoCyte stock in a transaction on Thursday, April 11th. The stock was acquired at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now directly owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Andrew Arno acquired 33,898 shares of OncoCyte stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.95 per share, with a total value of $99,999.10. Following the completion of the purchase, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The disclosure for this purchase can be found here. Insiders acquired a total of 2,457,288 shares of company stock valued at $7,176,400 in the last three months. 1.94% of the stock is currently owned by company insiders.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.